Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PCVX
SELLVaxcyte, Inc. · Healthcare · United States · $7.9B · Avg Vol: $89M/d
COMPANY DESCRIPTION
Vaxcyte, Inc. is a clinical-stage biotechnology company developing novel vaccines to prevent or treat infectious diseases. Its lead programs target pneumococcal disease and other bacterial infections, utilizing its proprietary cell-free protein synthesis platform. The company's competitive differentiation lies in its innovative platform technology, which aims to produce more effective and broader-spectrum vaccines.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 87.1M | — |
| EPS | -3.44 | -4.14 | -3.80 | -5.63 | — | -6.89 | -8.48 | -7.42 | — |
| Shares | 79.5M | 95.4M | 124.9M | 131.1M | +64.9% | 144.4M | — | — | — |
| Debt | 17.9M | 29.2M | 71.1M | 117.5M | 87.1% | 116.3M | — | — | — |
| Equity | 953.6M | 1.2B | 3.3B | 2.7B | 41.2% | — | — | — | — |
| Op CF | -170.6M | -296.8M | -452.6M | -655.6M | — | -769.9M | — | — | — |
| Inv CF | 74.6M | -773.3M | -2.0B | 437.4M | — | — | — | — | — |
| Fin CF | 861.5M | 639.8M | 2.4B | 2.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PCVX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PCVX | Vaxcyte, Inc.(you) | $7.9B | 27 | SELL |
| IBRX | ImmunityBio, Inc. | $7.4B | 26 | SELL |
| KYMR | Kymera Therapeutics, Inc. | $9.1B | 25 | SELL |
| COGT | Cogent Biosciences, Inc. | $6.8B | 25 | SELL |
| PRAX | Praxis Precision Medicines, Inc. | $9.1B | 29 | SELL |
| RYTM | Rhythm Pharmaceuticals, Inc. | $7.0B | 30 | SELL |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
| CGON | CG Oncology, Inc. | $6.1B | 24 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| ERAS | Erasca, Inc. | $6.6B | 31 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%